Odyssey Therapeutics (NASDAQ:ODTX) Cut to Sell at Wall Street Zen

Odyssey Therapeutics (NASDAQ:ODTX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. began coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating and a $26.00 price target on the stock. Oppenheimer reiterated an “outperform” rating and set a $40.00 price objective on shares of Odyssey Therapeutics in a research report on Thursday. TD Cowen assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued a “buy” rating for the company. Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued an “overweight” rating on the stock. Finally, Wedbush initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Odyssey Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Odyssey Therapeutics Price Performance

NASDAQ:ODTX opened at $19.07 on Friday. Odyssey Therapeutics has a 1 year low of $15.35 and a 1 year high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings data on Wednesday, June 17th. The company reported $999.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.31) by $1,000.31.

Insider Transactions at Odyssey Therapeutics

In related news, Director Shelley Chu bought 11,111 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $199,998.00. Following the acquisition, the director owned 11,111 shares in the company, valued at $199,998. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the transaction, the insider owned 1,831,383 shares in the company, valued at approximately $32,964,894. The trade was a 43.54% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 4,183,777 shares of company stock worth $75,319,986.